"保 申万宏源证券承销保荐有限责任公司 关于深圳市必易微电子股份有限公司 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"、 荐人"）作为深圳市必易微电子股份有限公司（以下简称"必易微"、 "公司"）首 次公开发行股票并在科创板上市的持续督导保荐人，根据《证券发行上市保荐业 务管理办法》《上海证券交易所科创板股票上市规则》以及《上海证券交易所上 市公司自律监管指引第 11 号——持续督导》等相关规定，负责必易微上市后的 持续督导工作，并出具本持续督导跟踪报告。 一、 持续督导工作情况 序号 工作内容 持续督导情况 建立健全并有效执行持续督导工作制度，并针 保荐人已建立健全并有效执行了持续督导 对具体的持续督导工作制定相应的工作计划。 制度，并制定了相应的工作计划。 根据中国证监会相关规定，在持续督导工作开 始前，与上市公司签署持续督导协议，明确双 保荐人已与必易微签订承销及保荐协议，已 方在持续督导期间的权利义务，并报上海证券 明确双方在持续督导期间的权利和义务。 交易所备案。 保荐人通过日常沟通、定期及不定期回访等 通过日常沟通、定期回访、现场检查、尽职调 查等方式开展持续督导工作。 展持续督 ...

Group 1 - A-shares experienced a collective rise, with the Shanghai Composite Index closing at 3420.57 points, up 1.15%, and the Shenzhen Component Index rising 1.68% to 10217.63 points [1][5] - The trading volume in the Shanghai and Shenzhen markets reached 14146 billion, a significant increase of 2920 billion compared to the previous day [1] - Key sectors such as electric power equipment, non-bank financials, and retail saw gains exceeding 2%, with solid performance from heavyweight stocks and a notable shift towards growth styles [1][6] Group 2 - *ST Jiuyou's stock plummeted over 80% after being placed in a delisting risk warning, with a market value reduced to 1.2 billion [2][4] - The company reported a negative net asset value at the end of 2023 and received an audit report with no opinion for its 2024 annual report, triggering delisting conditions [4] - Other companies in the delisting process also experienced severe declines, with some dropping over 70% on their first day of delisting [4] Group 3 - The electric power equipment index surged by 2.85%, and non-bank financials rose by 2.68%, indicating a bullish trend in these sectors [6] - The lithium battery sector saw significant gains, with multiple companies announcing advancements in solid-state battery technology and production timelines [6] - The humanoid robot sector also rebounded, with indices related to humanoid robots and associated technologies rising over 4% [6] Group 4 - A focus on high-growth small-cap stocks with significant R&D investment is highlighted, with 36 stocks identified that have over 20% of revenue allocated to R&D and projected net profit growth rates exceeding 40% from 2025 to 2027 [8] - Notable companies include Tai En Kang, which has seen a year-to-date increase of nearly 135%, driven by a strong pipeline of self-developed drugs [8][9] - The average increase for these identified companies is close to 19% year-to-date, outperforming the broader market [8]